Inhibition of Surfactin Biosynthesis in Bacillus Subtilis Using Cell‐Permeable Adenylation Domain Inhibitors
ChemBioChem · 2025
DOI: 10.1002/cbic.202500136 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Fumihiro Ishikawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka, 577-8502, Japan. Hauptthemen laut MEDLINE: Bacillus subtilis, Lipopeptides, Peptide Synthases, Peptides, Cyclic. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Uehara Memorial Foundation, Institute Foundation for Science, Osaka (IFO), Japan Foundation for Applied Enzymology.
Abstract (Originalsprache)
Several natural bacterial virulence factors are biosynthesized by nonribosomal peptide synthetases (NRPSs). Therefore, NRPSs producing such natural products have emerged as attractive antibiotic targets. N ‐(aminoacyl)sulfamoyladenosine (aminoacyl‐AMS) derivatives with chemical modifications at 2′‐OH group of the adenosine skeleton are previously reported that inhibit NRPS amino acid adenylation (A) domains in recombinant enzyme systems, cellular lysates, and bacterial cells. The introduction of a couple of functionalities at the 2′‐OH group preserves the binding affinity toward NRPS amino acid A‐domains and improves cell permeability of the AMS scaffold. However, the effects of these compounds on secondary metabolism have not yet been explored. In this study, an affinity‐based protein profiling (AfBPP) probe, L‐Leu‐AMS‐BPyne, is validated for in‐cell applications, including imaging of NRPS activities in bacteria. Next, L‐Leu‐AMS derivatives incorporating methyl, benzyl, and cyanomethyl functionalities at the 2′‐OH group are synthesized and their inhibitory activity toward intracellular surfactin‐NRPSs in the surfactin‐producer Bacillus subtilis ATCC 21332 are investigated using the AfBPP probe. Finally, the attenuation of surfactin production using a Leu‐AMS‐BPyne probe and L‐Leu‐AMS derivatives in B. subtilis is demonstrated. These results indicate that chemical modifications at the 2′‐OH group provide a way to develop cell‐permeable and functional NRPS A‐domain inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka, 577-8502, Japan.
- Department of System Chemotherapy and Molecular Sciences, Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto, 606-8501, Japan.
- School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
- Pharmaceutical Research and Technology Institute, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka, 577-8502, Japan.
ORCID-Profile: Fumihiro Ishikawa, Sho Konno, Genzoh Tanabe
Förderung
- Uehara Memorial Foundation
- Institute Foundation for Science, Osaka (IFO)
- Japan Foundation for Applied Enzymology
- Research Foundation for Pharmaceutical Sciences
- Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology
- Kindai University Research Enhancement Grant
- Anti-aging Project for Private Universities
Zitieren
APA
Ishikawa, F., Konno, S., Kakeya, H., & Tanabe, G. (2025). Inhibition of Surfactin Biosynthesis in Bacillus Subtilis Using Cell‐Permeable Adenylation Domain Inhibitors. ChemBioChem. https://doi.org/10.1002/cbic.202500136
Vancouver
Ishikawa F, Konno S, Kakeya H, Tanabe G. Inhibition of Surfactin Biosynthesis in Bacillus Subtilis Using Cell‐Permeable Adenylation Domain Inhibitors. ChemBioChem. 2025. doi:10.1002/cbic.202500136
BibTeX
@article{Ishikawa2025,
author = {Ishikawa, Fumihiro and Konno, Sho and Kakeya, Hideaki and Tanabe, Genzoh},
title = {Inhibition of Surfactin Biosynthesis in Bacillus Subtilis Using Cell‐Permeable Adenylation Domain Inhibitors},
journal = {ChemBioChem},
year = {2025},
doi = {10.1002/cbic.202500136}
}
EUVIMED